Literature DB >> 12018713

Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia.

Adnan M Al-Shaikh1, Mustafa H Abdullah, Andrew Barclay, Geraldine Cullen-Dean, Brian W McCrindle.   

Abstract

OBJECTIVE: To relate clinical factors to the development of cardiovascular atherosclerosis for patients with homozygous familial hypercholesterolemia.
BACKGROUND: Homozygous familial hypercholesterolemia is associated with extreme elevations in levels of cholesterol causing aggressive atherosclerosis.
METHODS: We reviewed 10 children, 8 of whom were male, assessed at a single institution. We found that individual characteristics, levels of lipid, cardiovascular investigations, and management were related to the activity of low density lipoprotein receptors.
RESULTS: Activity of low density lipoprotein receptors was defined as absent, being less than 2% of normal, in 4 patients who presented at the ages of 0.3, 1.4, 1.8, and 4.5 years, respectively. The activity was minimal, representing 5%-30% of normal, in another 4 patients presenting at the ages of 6.1, 9.6, 9.9, and 12 years, and was undetermined in 2 patients who presented at the ages of 3.5, and 12.1 years. Levels of low density lipoprotein cholesterol at presentation ranged from 12.2 to 24 millimoles per litre. Plasmapheresis was performed bi-weekly in 9 patients. Patients with absence of receptor activity were less likely to have a serial decrease in the levels of low density lipoprotein cholesterol prior to plasmapheresis, and one of these patients was increased to weekly plasmapheresis. In addition, they had more aggressive cardiovascular involvement of the coronary arteries, aortic valve and aorta, requiring surgical intervention at the age of 8 and 12 years in 2 patients, with sudden death at the age of 3.1 years in one patient. In contrast, 1 patient with minimal receptor activity had surgical intervention at the age of 16.6 years and another patient died suddenly at the age of 33.6 years.
CONCLUSION: Complete cardiac assessment is recommended at presentation. The frequency of plasmapheresis should be adjusted according to the activity of low density lipoprotein receptors and the individual response of the patient.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018713     DOI: 10.1017/s1047951102000240

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  7 in total

1.  A young male with familial hypercholesterolemia.

Authors:  Afzalur Rahman; Moeen Uddin Ahmed; A K M Monwarul Islam; Aparajita Karim; Shafiqul A Sarker
Journal:  J Saudi Heart Assoc       Date:  2012-08-04

2.  Fatal myocardial infarction at 4.5 years in a case of homozygous familial hypercholesterolaemia.

Authors:  Matthias Gautschi; Mladen Pavlovic; Jean-Marc Nuoffer
Journal:  JIMD Rep       Date:  2011-09-06

3.  Low-density lipoprotein apheresis: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-11-01

4.  Successful treatment of homozygous familial hypercholesterolemia using cascade filtration plasmapheresis.

Authors:  Fatih Kardaş; Aysun Cetin; Musa Solmaz; Rüksan Büyükoğlan; Leylagül Kaynar; Mustafa Kendirci; Bülent Eser; Ali Unal
Journal:  Turk J Haematol       Date:  2011-04-01       Impact factor: 1.831

Review 5.  Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied.

Authors:  Leo Ungar; David Sanders; Brian Becerra; Ailin Barseghian
Journal:  Front Cardiovasc Med       Date:  2018-08-30

6.  Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.

Authors:  Marina Cuchel; Eric Bruckert; Henry N Ginsberg; Frederick J Raal; Raul D Santos; Robert A Hegele; Jan Albert Kuivenhoven; Børge G Nordestgaard; Olivier S Descamps; Elisabeth Steinhagen-Thiessen; Anne Tybjærg-Hansen; Gerald F Watts; Maurizio Averna; Catherine Boileau; Jan Borén; Alberico L Catapano; Joep C Defesche; G Kees Hovingh; Steve E Humphries; Petri T Kovanen; Luis Masana; Päivi Pajukanta; Klaus G Parhofer; Kausik K Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Albert Wiegman; Olov Wiklund; M John Chapman
Journal:  Eur Heart J       Date:  2014-07-22       Impact factor: 35.855

7.  Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia.

Authors:  Xia Pu; Mark Sale; Feng Yang; Yi Zhang; John D Davis; Nidal Al-Huniti
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-10-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.